Pharma goes to Washington, Alnylam’s future, & Gilead’s dealmaking

Plus: Allison's struggles taking the T in Boston :( 

February 16, 2024 Check out STAT+

Sponsored By

Has PhRMA lost its fangs? Are 11th-hour changes ominous for clinical trials? And what's next in pain medicine? We cover all that and more this week on "The Readout LOUD," STAT's biotech podcast. The pharmaceutical industry, in court and in Congress, is working to water down legislation that will let Medicare negotiate certain drug prices. STAT Washington correspondent Rachel Cohrs joins us to explain the industry's struggle to make headway — and how it factors into the 2024 election. We also discuss the latest news in the life sciences, including a twist in the future of Alnylam Pharmaceuticals, competition to Vertex Pharmaceuticals' pain drug, and Gilead Sciences' latest acquisition. Listen Now Subscribe to the podcast to never miss an episode iTunes Google Spotify SoundCloud Podcast Addict TuneIn Visit the archive to see past episodes

---

---

Enjoying The Readout LOUD? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser